Download PDF

Work experience

Jan 2006Present

Director Business Development


 4-6 largest generic pharfmaceuticl company world wide. Turnover 2007 1,5 Billon Euro. Number of employeees 11.000

  • Portfolio and Launch management in Western Europe
  • Support to new markets
  • Market status and evaluation
  • Regualtory status and management
  • Patent evaluation
  • Profit and risk management
  • Secure launches on time
  • Due-Diligence of portfolio or company acqusitions
Oct 2003Dec 2005

Director Licensing


A medium sized pharmaceutical company and a major generic player focusing on generic products in US and Europe. Turnover 2003 was 1.3 billion USD (divided between API, Generics and Animal Health). Number of employees is4.500. All new product launches and organic growth were based on in-licensing.

Alpharma Generic Pharmacutical products was acquired by Actavis by December 2005

  • Identify relevant suppliers
  • Negotiate profitable deals for Alpharma
  • Make agreements covering up to a 5 year supply period.
  • Make relevant Business Cases (P&L and net present values are calculated andforms the basis of Go/No go decisions
  • Have the expenditure internally confirmed (CAPEX)
  • Negotiating the final contract (following the contract policy of Alpharma)
  • Final signing of contracts.


Besies the professional interest

  • Rowing (active since many years)
  • Running
  • Reading
  • Family


Male, married and have two grown up children.Educated as a Pharmacist from the Danish University of Pharmacy.Having more than 25 years of experience within the pharmaceutical industry. Last 15 years working internationally with Business to Business Sales, Marketing, Licensing and Business Development.

Currently holding the position as the Business DevelopmentDirector at Actavis, with responsibility for pipeline, portfolio and launch coordination for 12 countriesin Western Europe. Actavis acquired Alpharma generics in December 2005, where I held the position as In-Licensing Director, negotiating and acquiring new products for the generic pharmaceutical market in Europe.

Previous positions as;

Sales and Marketing Director at PolyPeptide Laboratories with global responsibility for sales of peptide products (API) and development services for the biotech and pharmaceutical industry. Growing the company from 50 to 350 employees and a turn over from 10 to 50 Mio USD.

Nordic Market Manager, at Nycomed with the responsibility for the sales in the Danish and Nordic markets.

The first 10 years of the carrier, working within pharmaceutical R&D, holding 3 patents.



M.SC. Pharm

University of Pharmacy (Denmark)


Danish English Swedish Norwegian  



Lean Six Sigma

Green Belt